Background: Left ventricular ejection function (LVEF) recovers in the majority of patients with aortic stenosis (AS) who undergo aortic valve replacement. However the outcomes of patients with low EF who undergo transcatheter aortic valve replacement (TAVR) are not well defined. Methods: Retrospective analysis of AS patients with normal versus mildly or severely impaired left ventricular function who underwent TAVR was done. Patients were divided according to baseline LVEF as normal (LVEF Ն 0.50), mild-moderate (0.40 Յ EF Ն 0.50) and severe (LVEFϽ0.40) dysfunction. Results: A total of 242 patients were included in the present analysis. 163 patients (67%) had normal LVEF, 43 had mild-moderate (18%) and 36 (15%) had severe LV dysfunction. Baseline demographics were generally comparable apart from higher rates of women and STS score among patients with LV dysfunction (Table) . There was no difference in access approach with 72% of the patient having transfemoral access. No significant difference in the in hospital and long term outcome were found (Table) . Conclusions: Patients with severe AS and impaired LV function who undergo TAVR may gain similar benefit from the procedure as patients with normal LV function.
Background: Edwards Sapien transcatheter valve is FDA approved for commercial use in non-operable patients with severe symptomatic aortic stenosis (AS) via the transfemoral approach. Objective: To assess the clinical profile and in-hospital complications in patients treated with commercial valve compared to PARTNER cohort B. Methods: Study included all consecutive patients treated with commercial Sapien valve at our institution. Baseline characteristics, clinical presentation and in-hospital complications were analyzed. Among all trasfemoral cases 37 commercial valve patients were compared to 54 patients in cohort B. Results: All clinical variables are similar between the groups including STS score (9.4Ϯ4 vs. 10.7Ϯ5, pϭ0.24) except commercial patients had more insulin dependent diabetes mellitus and dialysis dependent renal failure. In majority of the patients in the commercial arm the procedure was done with conscious sedation (81% vs. 56%, pϭ0.02). The use of planned surgical cut down for vascular access is also rare (4% vs. 85%, PϽ0.001) in commercial group. 100% procedural success in both the groups with valve deployment. There is trend for lower vascular and bleeding complications with less blood transfusion rates (27% vs. 59%, pϭ0.007) in the commercial patients. The in-hospital mortality and stroke rates are similar between the groups. Conclusions: The initial commercial use of the Edwards Sapien valve for inoperable patients reported to have similar success rates in valve deployment, in-hospital mortality and stroke rate when compared to PARTNER cohort B patients. The refinement in the procedure with more conscious sedation, experience of the operators and careful vascular planning with more percutaneous access in the commercial group lead to the trends for lower vascular complications and the requirement of blood transfusions.
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Clinical and procedural characteristics and in-hospital complications Failure to cross the leak with either the wire or the catheter occurred in two patients. In the other two patients, device was deployed with residual moderate regurgitation. There were no procedural or unexplained death, but there were two post procedural deaths, one patient had severe septic shock and the other had cardiogenic shock prior to intervention. No emergency surgery or device embolization occurred .One patient had an ischemic stroke in the fifth post-operative day. One patient with multiple defects and a failed attempt required an elective surgical repair to seal the leak. Conclusions: Percutaneous transcatheter closure of paravalvular leaks is feasible but appears to be technically demanding procedure with acceptable success rate especially in poor surgical candidate. Further experience is warranted to evaluate long term morbidity and mortality.
CRT-140
Percutaneous We identified 4 patients with significant FMR and limited exercise capacity due to HF. Significant ischemia was excluded with functional imaging. Surgical risk was deemed prohibitive. Mitral valve anatomy was assessed by transthoracic (TTE) and transesophageal echocardiography. Patients: One patient was female, 2 had AF, 3 had prior remote coronary artery bypass graft surgery, and the 4th had non-ischemic cardiomyopathy. Age was 59 Ϯ 11 years, BSA 1.7 Ϯ 0.1 m2, GFR 57.5 Ϯ 46.9mls/min, Hemoglobin 11.2 Ϯ 1.4g/dL. NYHA 2.75 Ϯ 0.5, LVEF 30 Ϯ 17%, MR grade 3.75 Ϯ 0.5, Six-Minute Walk Distance (6MWD) 208 Ϯ 132m, and Euroscore risk for cardiac surgery 32.9 Ϯ 26.9%. Results: All patients underwent successful MitraClip procedures without complication. Three patients used 1 clip, while 1 patient required 2 clips. MR grade was reduced to 1.25 Ϯ 0.5 and patients were discharged 2.25 Ϯ 0.96 days post MitraClip. Follow-up TTEs show durability of MR reduction (Fig 1.) . 6MWD improved to 423 Ϯ 92m (pϭ0.037). Two patients have resumed working, and all can participate in normal activities of daily living. They remain on standard pharmacotherapy for heart failure. Conclusion: In conclusion, MitraClip is safe and effective in restoring exercise capacity in selected patients with severe FMR and HF who are not surgical candidates.
